Abstract:Repression of the BCL11A protein could represent a therapeutic target for beta-hemoglobinopathies, as its knock-down has been shown to induce the expression of the fetal HBG (y-globin) gene ultimately leading to increased levels of the fetal hemoglobin tetramer (HbF, a2y2). In mice, Bcl11a is a key repressor of the murine HBG homolog Hbb-y. RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via pol III promoters has been used to modulate gene expression in a variety of mammalian cell types. However, we found a negative impact of Bcl11a knockdown on hematopoietic stem cells (HSCs), limiting the repopulation efficiency and long-term engraftment after genetic modification, which is a major impediment for its translation into human therapeutic applications. To achieve lineage-specific targeting of mRNAs in an attempt to reduce HSC toxicity, expression of shRNAs via pol II promoters is required, necessitating embedding the shRNA in mammalian microRNA (shRNAmir) sequences for expression and processing. To achieve optimal knockdown of the Bcl11a transcription factor in erythroid progenitor and precursor cells, we first compared the efficiency of mRNA modulation via pol III (U6-promoter) vs pol II (SFFV-promoter) based lentiviral vectors. We demonstrate a 100-1000 fold lower Hbb-y induction using shRNAmir vs pol III mediated shRNA vector backbones due to reduced Bcl11a knockdown efficiency. In order to understand the molecular basis for these differences, small RNA sequence analysis was performed on murine erythroleukemia cells (MEL) cells transduced by multiple shRNA–shRNAmir pairs. We show that shRNAs expressed via a U6 promoter yield guide strand sequences which differ by a 2-4 nt shift compared to pol II driven (shRNAmir) mature guide strand sequences. RNA sequencing demonstrated that the stretch of uridines making up part of the pol III termination signal is transcribed and included at the 3’ end of the shRNA. This results in the generation of mature guide strand sequences with an alternative seed sequence compared to the predicted sequence and compared to miRNA embedded shRNAs. The difference in the seed sequences between the two expression systems strongly influences the efficacy of target gene knockdown, leading to reduced knockdown in pol II based vectors. We engineered a 4bp shift into guide strands of shRNAmirs that resulted in a faithfully processed shRNA sequence (a mature guide strand sequence identical to U6-driven sh-RNAs) and improved knock-down efficiency of Bcl11a at the protein level in most cases. The improved knockdown of Bcl11a was associated with a 100-300-fold enhancement of Hbb-y induction in MEL cells. Based on these results, we propose a modified strategy for the prospective design of shRNAmirs derived from shRNA screens in pol III vector backbones to achieve lineage-specific regulation of target genes. Targeted expression of shRNAmiRs to the erythroid compartment driven by a b-globin promoter/LCR element circumvented the detrimental effect on HSC engraftment, while still mediating efficient BCL11A knockdown, leading to high y-globin induction and formation of substantial amounts of fetal hemoglobin in human CD34-derived erythroid cells in vitro.

A tetramer of BCL11A is required for stable protein production and fetal hemoglobin silencing

Transcriptional Repressor BCL11A in Erythroid Cells

Structural Insights into the DNA-Binding Mechanism of BCL11A: The Integral Role of ZnF6

Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin

Structural basis for human ZBTB7A action at the fetal globin promoter

Fibrillarin modulates fetal hemoglobin silencing

Abstract 4746: Amelioration of hemoglobinopathies by targeted deletion of zinc finger domain within BCL11A gene using CRISPR-Cas9 technology

Molecular basis of polycomb group protein-mediated fetal hemoglobin repression

Optimization Of Bcl11a Knockdown By Mirna Scaffold Embedded Shrnas Leading To Enhanced Induction Of Fetal Hemoglobin In Erythroid Cells For The Treatment Of Beta-Hemoglobinopathies

The Protein Methyltransferase Prmt5 Links Histone H4 Methylation to Dnmt3a-dependent DNA Methylation and Transcriptional Silencing of the Fetal Globin Genes

Proteomics Screening Uncovers HMGA1 As a Promising Negative Regulator for Γ-Globin Expression in Response to Decreased Β-Globin Levels

Elevating fetal hemoglobin - recently discovered regulators and mechanisms

Identification of a PRMT5-dependent repressor complex linked to silencing of human fetal globin gene expression.

An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level

Dominant-negative C/ebpα and Polycomb Group Protein Bmi1 Extend Short-Lived Hematopoietic Stem/progenitor Cell Life Span and Induce Lethal Dyserythropoiesis

3’HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

Innovative Transformer Base Editor (Tbe)-Mediated Editing at BCL11A Binding Motif Triggers High Level of Γ-Globin Expression with No Observable Off-Target Mutations

3′HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia

Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathies